Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan

Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)

(2015) Shunsuke Mori et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis

(2015) Manjari Lahiri et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

(2015) K. Yamamoto et al.   JOURNAL OF RHEUMATOLOGY

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

(2015) Jasvinder A Singh et al.   LANCET

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

(2015) Vibeke Strand et al.   ARTHRITIS RESEARCH & THERAPY

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

(2015) Ryoko Sakai et al.   ARTHRITIS RESEARCH & THERAPY

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare

(2015) Huifeng Yun et al.   Arthritis & Rheumatology

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs

(2015) Neil A. Accortt et al.   Arthritis & Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials

(2014) Tzeyu L. Michaud et al.   AMERICAN JOURNAL OF MEDICINE

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy

(2014) Huifeng Yun et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

(2014) J. R. Curtis et al.   ARTHRITIS CARE & RESEARCH

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid Arthritis Disease Activity and Disability Affect the Risk of Serious Infection Events in RADIUS 1

(2013) A. Weaver et al.   JOURNAL OF RHEUMATOLOGY

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan

(2013) T. Koike et al.   JOURNAL OF RHEUMATOLOGY

Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales

(2013) John P. A. Ioannidis et al.   Nature Reviews Rheumatology

Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis

(2013) Stephen S. Johnston et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Sanne A A van Dartel et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

(2012) Kalle J. Aaltonen et al.   PLoS One

Overview of safety of non-biologic and biologic DMARDs

(2012) E. M. Ruderman   RHEUMATOLOGY

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

(2011) J. R. Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

(2011) K. Au et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials

(2011) Andrew E. Thompson et al.   ARTHRITIS AND RHEUMATISM

Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care

(2011) Jeffrey R. Curtis et al.   CLINICAL THERAPEUTICS

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

(2011) Y. KOMANO et al.   JOURNAL OF RHEUMATOLOGY

TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis

(2011) Michael A. Lane et al.   MEDICINE

An observational study of tocilizumab and TNF-  inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety

(2011) K. Yoshida et al.   RHEUMATOLOGY

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

(2010) L. Campbell et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

(2009) J D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

(2008) J P Leombruno et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM